Vismodegib for periocular basal cell carcinoma: an international multicentre case series
| Autor: | Daniel S Morris, K. Chan, Saul Rajak, P. Norris, M. Cranstoun, H. Oliphant, A. Haridas, M. R. Edmunds, Lucy Clarke, M. Althaus, Timothy J. Sullivan, J. Laybourne |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Skin Neoplasms Pyridines Locally advanced Vismodegib Antineoplastic Agents Article 03 medical and health sciences 0302 clinical medicine Partial response medicine Carcinoma Humans Anilides Hedgehog Proteins Basal cell carcinoma Complete response Retrospective Studies business.industry Medical record Australia Retrospective cohort study medicine.disease United Kingdom Surgery Ophthalmology Treatment Outcome Carcinoma Basal Cell 030221 ophthalmology & optometry Female Neoplasm Recurrence Local business 030217 neurology & neurosurgery New Zealand medicine.drug |
| Zdroj: | Eye (Lond) |
| ISSN: | 1476-5454 0950-222X |
| DOI: | 10.1038/s41433-020-0778-3 |
| Popis: | INTRODUCTION: Vismodegib (Erivedge, Genentech) is a first-in-class inhibitor of the hedgehog (Hh) pathway, which is licensed for use in locally advanced basal cell carcinoma (BCC) and metastatic BCC. The National Institute for Health and Care Excellence withdrew recommendation for use of vismodegib secondary to a lack of data comparing vismodegib to standard supportive care. The purpose of this multicentre, international case series is to report outcomes of patients with locally advanced periocular BCC who have been treated with vismodegib. METHODS: The medical records of all patients treated with vismodegib were retrospectively reviewed across seven institutions in the United Kingdom, Australia, and New Zealand. RESULTS: Thirteen patients were identified. Seven (54%) patients were male. All BCCs were ill-defined, with seven (58%) having orbital involvement at presentation. Median treatment time was 7 months (range 2–36 months). Eleven out of 13 patients developed side effects, the most common being fatigue in six patients (46%). Median follow-up was 24 months (range 12–48 months). Complete response was found in 5/13 patients (38%) and a partial response in 8/13 patients (62%). Six patients had further surgery after vismodegib, with three classed as globe-sparing operations. Three patients developed recurrence (23%). Three patients (23%) ultimately underwent exenteration. DISCUSSION: This study demonstrates vismodegib to be a well-tolerated treatment which may, in some cases, facilitate globe-sparing surgery and hence avoid disfiguring operations such as exenteration. Uncertainty does remain regarding the long-term outcomes of patients treated with vismodegib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink